(Q46664625)

24 December 2017

title

Hepatotoxicity of pyrazinamide: cohort and case-control analyses (English)

1 reference

24 December 2017

1 reference

1 reference

Kwok C Chang

1

1 reference

24 December 2017

Chi C Leung

2

1 reference

24 December 2017

Wing W Yew

3

1 reference

24 December 2017

Tat Y Lau

4

1 reference

24 December 2017

Cheuk M Tam

5

1 reference

24 December 2017

language of work or name

English

0 references

publication date

3 April 2008

1 reference

24 December 2017

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

24 December 2017

volume

177

1 reference

24 December 2017

issue

12

1 reference

24 December 2017

page(s)

1391-1396

1 reference

24 December 2017

A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

The action of antituberculosis drugs in short-course chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

Geographical distribution of tuberculosis notifications in national surveys of England and Wales in 1988 and 1993: report of the Public Health Laboratory Service/British Thoracic Society/Department of Health Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

Pyrazinamide-induced granulomatous hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

Tuberculosis chemotherapy: still a double-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

Side effects of antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

Anti-tuberculosis medication and the liver: dangers and recommendations in management

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

An official ATS statement: hepatotoxicity of antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

Liver injury during antituberculosis treatment: an 11-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

Frequency and type of reactions to antituberculosis drugs: observations in routine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200802-355OC

10.1164/RCCM.200802-355OC

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

18388355

1 reference

24 December 2017